We are live on ! Find out more
CP

Catalys Pacific Portfolio holdings

AUM $229M
1-Year Est. Return 100.3%
This Fund
S&P 500
This Quarter Est. Return
-4.02%
1 Year Est. Return
+100.3%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$107M
AUM Growth
Cap. Flow
+$95.8M
Cap. Flow %
89.81%
Top 10 Hldgs %
100%
Holding
3
New
3
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$72.2M
2
HLVX
HilleVax
HLVX
+$17.4M
3
PHAT icon
Phathom Pharmaceuticals
PHAT
+$6.22M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MLYS icon
1
Mineralys Therapeutics
MLYS
$2.34B
$79.1M 74.13%
+9,194,579
New +$72.2M
HLVX
2
DELISTED
HilleVax
HLVX
$21M 19.69%
+1,308,974
New +$17.4M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$678M
$6.59M 6.18%
+721,962
New +$6.22M

Similar funds

Catalys Pacific's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Catalys Pacific, which disclosed 3 positions worth $107M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Mineralys Therapeutics: 9,194,579 shares worth $79.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Catalys Pacific's largest Q4 2023 buy was Mineralys Therapeutics: 9,194,579 shares worth $79.1M.
  • Catalys Pacific's ten largest holdings make up 100% of its $107M portfolio in Q4 2023.
  • Catalys Pacific disclosed 3 positions in Q4 2023, its first 13F filing on record.

Based on Catalys Pacific's 13F filing for Q4 2023, filed 14 Feb 2024.